SCHEMBL6448552

SCHEMBL6448552

CCOC(=O)c1cc(-c2ccc(NC(=O)c3ccc(C(=O)Nc4nnc(-c5cc(Cl)cc(Cl)c5O)s4)cc3)cc2)oc1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACR P10323 2/20 0.44
DDX3X O00571 1/20 0.41
KMT2A Q03164 3/20 0.40
HPGD P15428 3/20 0.40
MEN1 O00255 2/20 0.40
POLB P06746 2/20 0.40
KDM4E B2RXH2 2/20 0.40
MAPT P10636 5/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
HSD17B10 Q99714 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
TSHR P16473 1/20 0.39
TP53 P04637 3/20 0.38
USP2 O75604 1/20 0.38
PTPN7 P35236 1/20 0.38
BRCA1 P38398 1/20 0.38
DUSP3 P51452 1/20 0.38
PTPN11 Q06124 1/20 0.38
ALDH1A1 P00352 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6445843 0.81 MAPT (0.52) KMT2AHPGDMEN1POLBMAPT
SCHEMBL6447209 0.80 MAPT (0.44) DDX3XKMT2AHPGDMEN1POLB
SCHEMBL6453685 0.80 MAPT (0.54) KMT2AMEN1POLBKDM4EMAPT
SCHEMBL6444242 0.79 RAB9A (0.52) KMT2AHPGDMEN1POLBKDM4E
SCHEMBL6322386 0.79 TRPV1 (0.53) KMT2AHPGDMEN1POLBMAPT
SCHEMBL6447202 0.78 KMT2A (0.46) KMT2AMEN1POLBKDM4EMAPT
SCHEMBL6449238 0.78 CSNK2A2 (0.52) KMT2AMEN1POLBKDM4EMAPT
SCHEMBL6445978 0.77 SNCA (0.47) KMT2AMEN1POLBKDM4ESMN1; SMN2
SCHEMBL6447057 0.77 KMT2A (0.52) KMT2AHPGDMEN1POLBKDM4E
SCHEMBL6325807 0.77 TRPV1 (0.51) KMT2AHPGDMEN1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 BRISTOL-MYERS SQUIBB COMPANY 2005-06-30 US claimed
WO-2023099719-A1 EXPANDABLE PROTECTIVE COATING H. K. WENTWORTH LIMITED (GB) 2023-06-08 WO disclosed
EP-1606373-A1 FABRIC CARE COMPOSITIONS COMPRISING CATIONIC STARCH THE PROCTER & GAMBLE COMPANY (US) 2005-12-21 EP disclosed
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 BRISTOL-MYERS SQUIBB COMPANY 2005-06-30 US disclosed
WO-2004087854-A1 FABRIC CARE COMPOSITIONS COMPRISING CATIONIC STARCH THE PROCTER & GAMBLE COMPANY (US) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 SERPINE1, SERPINC1, SERPINB1 ACR 2444/4885DDX3X 4246/4885KMT2A 3566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.